The introduction of agents such as ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), and pembrolizumab (anti-PD-1) marked a pivotal shift in treatment paradigms, as these therapies block inhibitory immune checkpoints, restore T-cell activity, and have demonstrated improved overall survival in patients with advanced melanoma [2,3]. This evidence concerns the gene PDCD1 and melanoma.